Heike Schmolck, MD
Neurology · Des Moines, IANPI 1972646917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,268 and has fallen 79.6% since, to $258 in 2025.
Across 147 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$553
- Biogen$435
- Novartis$172
- Supernus Pharmaceuticals, Inc.$139
- Amgen$100
- Lilly USA, LLC$97
- plus $983 from 27 others
What the payments were for
- Speaking & faculty fees$703%
- Food & beverage$2,40897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $553 |
| Biogen | 16 | $435 |
| Novartis | 13 | $172 |
| Supernus Pharmaceuticals, Inc. | 18 | $139 |
| Amgen | 5 | $100 |
| Lilly USA, LLC | 7 | $97 |
| UCB, Inc. | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 6 | $93 |
| EMD Serono, Inc. | 3 | $79 |
| Acorda Therapeutics, Inc | 4 | $70 |
| Pfizer | 4 | $67 |
| Argenx US, Inc. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| GE HealthCare | 2 | $49 |
| Eisai Inc. | 2 | $41 |
| SK Life Science, Inc. | 1 | $38 |
| Merz North America, Inc. | 2 | $36 |
| Tanabe Pharma America, Inc. | 2 | $33 |
| CSL Behring | 1 | $32 |
| Upsher-smith Laboratories LLC | 2 | $30 |
| MDD US Operations, LLC | 2 | $28 |
| Genentech USA, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Adamas Pharmaceuticals, Inc. | 1 | $13 |
| Promius Pharma LLC | 1 | $12 |
| Sanofi | 1 | $12 |
How this compares
$2,478 in reported general payments places this provider in the 70th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 16 | $61,178 |
| QuliptaAtogepant | 40 | $52,692 |
| TopamaxTopiramate | 16 | $40,361 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $33,396 |
| UbrelvyUbrogepant | 26 | $27,599 |
| VimpatLacosamide | 24 | $22,189 |
| Rivastigmine | 110 | $19,714 |
| BriviactBrivaracetam | 13 | $18,073 |
| Nurtec OdtRimegepant Sulfate | 15 | $15,015 |
| FycompaPerampanel | 14 | $14,984 |
| ExelonRivastigmine | 21 | $14,452 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $10,929 |
| Lacosamide | 41 | $10,414 |
| Galantamine ErGalantamine Hbr | 126 | $9,157 |
| Donepezil Hcl | 1,046 | $8,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $553 | $80,29066 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $51 | $61,17816 claims |
| UCB, Inc.Vimpat, Briviact | $95 | $40,26137 claims |
| PfizerNurtec Odt | $67 | $15,01515 claims |
| Eisai Inc.Fycompa | $41 | $14,98414 claims |
| NovartisExelon | $172 | $14,45221 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $18 | $1,99920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.